OncoPharm

We finish discussing the 2018 FDA-approvals (calaspargase, ravulizumab, tazgraxofusp).

Discover the latest insights on the modified FOLFIRINOX regimen for pancreatic cancer. Delve into the findings of the PRODIGE-24 study and its implications for adjuvant therapies. The conversation navigates the complexities of treatment, including potential benefits and complications like neuropathy. Engaging discussions highlight the evolution of cancer treatments and encourage audience participation in oncology topics.

Keeping it light this Holiday Season with a discussion of the portrayal of pharmacists, notably Mr. Gower from It's a Wonderful Life, in pop culture. Regular Pods return in 2019.

This discussion dives into the FOLFOX chemotherapy regimen and its significant impact on treating stage II and III colon cancer. It examines the historical development of 5-FU and clinical trials proving FOLFOX's efficacy and safety. The conversation also highlights the innovative CAPEX regimen, a three-week schedule involving capecitabine, and compares it to traditional treatments. The ongoing evolution in chemotherapy practices aims to improve effectiveness while minimizing side effects, marking important advancements in oncology pharmacy.

Another week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F1078155218802620

The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.

Describing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.

Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.

Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?

Running through recent notable updates on pembrolizumab, olaparib, atezolizumab, palbociclib and 5F9's introduction.